TITLE

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

AUTHOR(S)
Oden-Gangloff, A.; Di Fiore, F.; Bibeau, F.; Lamy, A.; Bougeard, G.; Charbonnier, F.; Blanchard, F.; Tougeron, D.; Ychou, M.; Boissière, F.; Le Pessot, F.; Sabourin, J.-C.; Tuech, J.-J.; Michel, P.; Frebourg, T.; Boissière, F
PUB. DATE
April 2009
SOURCE
British Journal of Cancer;4/21/2009, Vol. 100 Issue 8, p1330
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Recent studies have suggested that activation of the EGFR pathway leads to malignant transformation only if the p53 protein is inactivated. Therefore, we evaluated the impact of TP53 mutations on cetuximab-based chemotherapy (CT) sensitivity in combination with KRAS mutations that have been associated with cetuximab resistance. KRAS and TP53 status were assessed in tumours from 64 metastatic colorectal cancer patients treated with cetuximab-based CT and correlated to clinical response using the Fisher's exact test. Times to progression (TTPs) according to gene status were calculated using the Kaplan-Meier method and compared with log-rank test. TP53 mutations were found in 41 patients and were significantly associated with controlled disease (CD), as defined as complete response, partial response or stable disease (P=0.037) and higher TTP (20 vs 12 weeks, P=0.004). Remarkably, in the subgroup of 46 patients without KRAS mutation, but not in patients with KRAS mutation, TP53 mutations were also associated with CD (P=0.008) and higher TTP (24 vs 12 weeks, P=0.0007). This study suggests that TP53 mutations are predictive of cetuximab sensitivity, particularly in patients without KRAS mutation, and that TP53 genotyping could have a clinical interest to select patients who should benefit from cetuximab-based CT.
ACCESSION #
37591412

 

Related Articles

  • Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Weidlich, S.; Walsh, K.; Crowther, D.; Burczynski, M. E.; Feuerstein, G.; Carey, F. A.; Steele, R. J. C.; Wolf, C. R.; Miele, G.; Smith, G. // British Journal of Cancer;7/4/2011, Vol. 105 Issue 2, p246 

    Background: The epidermal growth factor receptor-targeted monoclonal antibody cetuximab (Erbitux) was recently introduced for the treatment of metastatic colorectal cancer. Treatment response is dependent on Kirsten-Ras (K-Ras) mutation status, in which the majority of patients with...

  • Synergy Between Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract. Mahtani, Reshma L.; Macdonald, John S. // Oncologist;Jan2008, Vol. 13 Issue 1, p1 

    Cetuximab is a recently approved monoclonal antibody that targets the epidermal growth factor receptor, a receptor tyrosine kinase involved in the development and progression of colorectal cancer (CRC) and other solid tumors. Cetuximab, as a single agent or in combination with chemotherapy, has...

  • KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. Messner, Isabelle; Cadeddu, Giuseppe; Huckenbeck, Wolfgang; Knowles, Helen; Gabbert, Helmut; Baldus, Stephan; Schaefer, Karl-Ludwig // Journal of Cancer Research & Clinical Oncology;Feb2013, Vol. 139 Issue 2, p201 

    Purpose: Targeted therapies using the anti-EGFR antibodies panitumumab (Pmab) or cetuximab (Cmab) are currently restricted to patients with metastatic colorectal adenocarcinoma whose tumours do not show a mutation in KRAS. However, recent retrospective studies indicated that patients with...

  • A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Tian, Sun; Simon, Iris; Moreno, Victor; Roepman, Paul; Tabernero, Josep; Snel, Mireille; van't Veer, Laura; Salazar, Ramon; Bernards, Rene; Capella, Gabriel // Gut;Apr2013, Vol. 62 Issue 4, p540 

    Objective To develop gene expression profiles that characterise KRAS-, BRAF- or PIK3CA-activatedtumours, and to explore whether these profiles might be helpful in predicting the response to the epidermal growth factor receptor (EGFR) pathway inhibitors better than mutation status alone. Design...

  • Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. Pentheroudakis, George; Kotoula, Vassiliki; De Roock, Wendy; Kouvatseas, George; Papakostas, Pavlos; Makatsoris, Thomas; Papamichael, Demetris; Xanthakis, Ioannis; Sgouros, Joseph; Televantou, Despina; Kafiri, Georgia; Tsamandas, Athanassios C.; Razis, Evangelia; Galani, Eleni; Bafaloukos, Dimitrios; Efstratiou, Ioannis; Bompolaki, Iliada; Pectasides, Dimitrios; Pavlidis, Nicholas; Tejpar, Sabine // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy. Methods:...

  • Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ciardiello, F.; Normanno, N.; Maiello, E.; Martinelli, E.; Troiani, T.; Pisconti, S.; Giuliani, F.; Barone, C.; Cartenì, G.; Rachiglio, A. M.; Montesarchio, V.; Tonini, G.; Rizzi, D.; Cinieri, S.; Bordonaro, R.; Febbraro, A.; De Vita, F.; Orditura, M.; Fenizia, F.; Lambiase, M. // Annals of Oncology;Sep2014, Vol. 25 Issue 9, p1756 

    In this study, we developed and validated a next-generation sequencing gene panel covering 22 different genes that have been fully sequenced in multiple exons to cover >500 potential mutation sites. The results show that the technique is feasible, reproducible and could be done with a high...

  • The Laboratory Assessment of KRAS Mutation Status in Colorectal Cancer. Karapetis, Christos S; Snell, Lesley E // Asia Pacific Journal of Oncology & Hematology;2010, Vol. 2 Issue 1, p75 

    Mono clonal antibodies that bind to the epidermal growth factor receptor (EGER), particularly cetuximab and panitumumab, can improve overall survival and prolong progression-free survival in patients with advanced colorectal cancer. However, approximately 40% of patients will have tumours that...

  • KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Malapelle, U; Carlomagno, C; Salatiello, M; De Stefano, A; De Luca, C; Bianco, R; Marciano, R; Cimminiello, C; Bellevicine, C; De Placido, S; Troncone, G // British Journal of Cancer;8/7/2012, Vol. 107 Issue 4, p626 

    Background:Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are restricted to KRAS wild-type (WT) metastatic colorectal cancers (mCRCs), usually identified by direct sequencing, that may yield false negative results because of genetic heterogeneity within the tumour. We...

  • A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. Yoshida, Michihiro; Shimura, Takaya; Sato, Mikinori; Ebi, Masahide; Nakazawa, Takahiro; Takeyama, Hiromitsu; Joh, Takashi // Journal of Cancer Research & Clinical Oncology;Mar2013, Vol. 139 Issue 3, p367 

    Purpose: Although KRAS mutation has been identified as a negative predictive biomarker of anti-EGFR antibodies in metastatic colorectal cancer (mCRC), the efficacy in mCRC patients with KRAS wild-type status remains limited. Anti-EGFR antibodies work by blocking ligand binding, but the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics